Philippe Gabriel Steg, MD, discusses the full results of the terminated trial, reflecting on their impact on the ongoing LIBREXIA-AF and LIBREXIA-Stroke trials.
Philippe Gabriel Steg, MD
Advertisement
Philippe Gabriel Steg, MD, is a professor of cardiology at the Université Paris and the chief of the department of cardiology and director of the coronary care unit at Hôpital Bichat.
Articles by Philippe Gabriel Steg, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
ESC Congress 2026: Day 1 Recap—5 Headlines to Know
2
2026 ESC Guidelines for Heart Failure Redefine Disease and Treatment Subtypes
3
Tirzepatide Gets FDA Approval to Cut Cardiovascular Risk in Type 2 Diabetes
4
Treating ATTR-CM With Urgency: How Strength in TTR Silencing Is Helping Change the Course of Patient Care
5